Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
The University of Queensland
M.D. Anderson Cancer Center
Changzhou No.2 People's Hospital
BioNTech SE
Institut du Cancer de Montpellier - Val d'Aurelle
Children's Hospital of Philadelphia
Amgen
Orca Biosystems, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Corcept Therapeutics
Memorial Sloan Kettering Cancer Center
University Hospital, Clermont-Ferrand
National Cancer Institute (NCI)
EMD Serono
Wake Forest University Health Sciences
TaiRx, Inc.
Genmab
M.D. Anderson Cancer Center
Section for Affective Disorders; Northern Stockholm Psychiatry
Merck Sharp & Dohme LLC
Medical University of South Carolina
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AbbVie
TaiRx, Inc.
National Institutes of Health Clinical Center (CC)
Hoosier Cancer Research Network
USWM, LLC (dba US WorldMeds)
USWM, LLC (dba US WorldMeds)
Nuclear Imaging Institute
University Hospital, Lille
M.D. Anderson Cancer Center
Amgen
Centre hospitalier de l'Université de Montréal (CHUM)
Georgetown University
Assistance Publique - Hôpitaux de Paris
AbbVie
Astellas Pharma Inc
Actuate Therapeutics Inc.
Celgene
American Society of Clinical Oncology
Grupo Espanol de Tumores Neuroendocrinos
Bristol-Myers Squibb
Seattle Institute for Biomedical and Clinical Research
National Institutes of Health Clinical Center (CC)
Boston Scientific Corporation
Eli Lilly and Company
Cedars-Sinai Medical Center